Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
Jean-Yves Blay, Quentin Devin, Florence Duffaud, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1163-1175
Closed Access | Times Cited: 12

Showing 12 citing articles:

A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.
Jean‐Yves Blay, Camille Schiffler, Olivier Bouché, et al.
Annals of Oncology (2024)
Open Access | Times Cited: 12
Gastrointestinal Stromal Tumors
Gal Strauss, Suzanne George
Current Oncology Reports (2025)
Closed Access | Times Cited: 1
GIST: Imatinib nicht unterbrechen

Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 01, pp. 18-18
Closed Access
GIST: Imatinib nicht unterbrechen

TumorDiagnostik & Therapie (2025) Vol. 46, Iss. 02, pp. 86-88
Closed Access
Next questions on gastrointestinal stromal tumors: unresolved challenges and future directions
D. Romandini, Paweł Sobczuk, Carlo María Cicala, et al.
Current Opinion in Oncology (2025)
Closed Access
Duration of adjuvant imatinib treatment in GIST at high risk of relapse
Erman Akkuş
Annals of Oncology (2024) Vol. 35, Iss. 12, pp. 1205-1206
Closed Access | Times Cited: 2
Imatinib in advanced GIST: if it's working, don’t stop a good thing
Ryan A. Denu, Neeta Somaiah
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1105-1107
Closed Access
Long-term adjuvant therapy for high-risk GIST: towards tailored imatinib duration?
Toshirou Nishida, Robin L. Jones
Annals of Oncology (2024)
Closed Access
Omitting study limitations might have implications for the patients – Authors' reply
Jean-Yves Blay, Sylvie Chabaud, David Pérol, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 11, pp. e538-e538
Closed Access
Omitting study limitations might have implications for the patients
Paul de Boissieu, Sylvie Chevret
The Lancet Oncology (2024) Vol. 25, Iss. 11, pp. e537-e537
Closed Access
Actualités 2024 par le Comité dé rédaction du Bulletin du Cancer : congrès ASCO, ESMO et au-delà
Stéphane Vignot, Audrey Bellesœur, Carole Bouleuc, et al.
Bulletin du Cancer (2024) Vol. 112, Iss. 1, pp. 19-34
Open Access
Advancement in medical treatment for gastrointestinal stromal tumors (GISTs): a ray of hope
H. B. Singh, Sourav Mohanto, Hitesh Chopra, et al.
Annals of Medicine and Surgery (2024) Vol. 87, Iss. 3, pp. 1383-1393
Open Access
Page 1

Scroll to top